Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03993327 · ClinicalTrials.gov registry record · Phase 1

An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer

A Phase 1 study of Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v8, sponsored by City of Hope Medical Center.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target
1
Study location

NCT03993327 is a Phase 1 study of Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v8 that has completed, run by City of Hope Medical Center. The registered enrollment target is 4 participants, below the 89-participant average among 22 other Metastatic Colorectal Carcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03993327, a Phase 1 study of Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v8, has completed, sponsored by City of Hope Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies how well an imaging agent called I-124 M5A works in detecting CEA-positive colorectal cancer that has spread to the liver. I-124 M5A is a monoclonal antibody, called M5A, linked to a radioactive substance called I-124. M5A binds to CEA-positive cancer cells and may, through imaging scans, be able to detect liver metastases by picking up signals from I-124.

Conditions Studied

Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Colorectal Carcinoma Metastatic in the Liver

Interventions

  • PROCEDURE Positron Emission Tomography
  • BIOLOGICAL Iodine I 124 Monoclonal Antibody M5A

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2020-07-15
Est. Completion 2024-06-04
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03993327

The ClinicalTrials.gov registry entry for NCT03993327 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 22 other Metastatic Colorectal Carcinoma trials with a reported enrollment target (96% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Metastatic Colorectal Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography is the first listed.

NCT03993327 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03993327 about?

NCT03993327 is a clinical study titled "An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer". This phase I trial studies how well an imaging agent called I-124 M5A works in detecting CEA-positive colorectal cancer that has spread to the liver. I-124 M5A is a monoclonal antibody, called M5A, linked to a radioactive substance called I-124. M5A binds to CEA-positive cancer cells and may, throug...

What is the current status of trial NCT03993327?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-07-15. Estimated completion is 2024-06-04.

What conditions does trial NCT03993327 study?

This clinical trial studies the following conditions: Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8.

What interventions are being tested in trial NCT03993327?

The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Iodine I 124 Monoclonal Antibody M5A (BIOLOGICAL).

Who is sponsoring clinical trial NCT03993327?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03993327 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Colorectal Carcinoma

All registered trials for this condition

Stage IV Colorectal Cancer AJCC v8

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.